PMID- 23616245
OWN - NLM
STAT- MEDLINE
DCOM- 20140506
LR  - 20140304
IS  - 1099-1069 (Electronic)
IS  - 0278-0232 (Linking)
VI  - 31
IP  - 4
DP  - 2013 Dec
TI  - Low-dose cytarabine and aclarubicin combined with granulocyte colony-stimulating 
      factor for the treatment of relapsed or primary refractory acute lymphocytic 
      leukemia: a retrospective study of 25 Chinese patients.
PG  - 206-12
LID - 10.1002/hon.2051 [doi]
AB  - Despite improvements in treatment, the prognosis of relapsed or primary 
      refractory acute lymphocytic leukemia (ALL) remains poor, and outcomes are worse 
      in older adults with the short first complete remission (CR). Attainment of the 
      second CR by salvage therapy would improve the survival of these patients and may 
      enable them to undergo curative treatment with allogeneic hematopoietic stem cell 
      transplantation. The fact that there are diverse salvage protocols for these 
      adult patients but without a striking CR-induction efficacy indicates that 
      efforts are still needed to indentify new effective reinduction regimens. In this 
      study, the CAG regimen (cytarabine, 10 mg/m(2) subcutaneously every 12 h on days 
      1-14; aclarubicin, 5-7 mg/m(2) intravenously daily on days 1-8; and concurrent 
      granulocyte colony-stimulating factor, 200 microg/m(2) /day subcutaneously) was 
      administered to 25 patients with relapsed or refractory ALL, including 11 T-cell 
      ALL (T-ALL) and 14 B-cell (B-ALL) patients (age range, 11-61 years; median age, 
      26 years), to assess its efficacy as a salvage therapy. One course of the CAG 
      regimen resulted in an overall response [CR or partial remission (PR)] rate of 
      64%, a CR rate of 56% and generally mild adverse effects. An overall response was 
      observed in all 11 T-ALL patients (10 CR and 1 PR) and 35.7% of B-ALL patients 
      (p = 0.0009). The significant treatment potential of CAG regimen for relapsed or 
      primary refractory ALL, especially for T-ALL patients, described in this report 
      would prepare them for a second CR to pursue longer survival.
CI  - Copyright (c) 2013 John Wiley & Sons, Ltd.
FAU - Xue, Sheng-Li
AU  - Xue SL
AD  - Department of Hematology, The First Affiliated Hospital of Soochow University, 
      Suzhou, China; Jiangsu Institute of Hematology, The First Affiliated Hospital of 
      Soochow University, Suzhou, China; Key Laboratory of Thrombosis and Hemostasis of 
      Ministry of Health, The First Affiliated Hospital of Soochow University, Suzhou, 
      China.
FAU - Cui, Hong-Xia
AU  - Cui HX
FAU - Zou, Jing-Ying
AU  - Zou JY
FAU - Xue, Meng-Xing
AU  - Xue MX
FAU - Tang, Xiao-Wen
AU  - Tang XW
FAU - Zhang, Yan-Ming
AU  - Zhang YM
FAU - Wu, De-Pei
AU  - Wu DP
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130425
PL  - England
TA  - Hematol Oncol
JT  - Hematological oncology
JID - 8307268
RN  - 04079A1RDZ (Cytarabine)
RN  - 143011-72-7 (Granulocyte Colony-Stimulating Factor)
RN  - 74KXF8I502 (Aclarubicin)
RN  - CAG protocol
SB  - IM
MH  - Aclarubicin/administration & dosage
MH  - Adolescent
MH  - Adult
MH  - Antineoplastic Combined Chemotherapy Protocols/administration & 
      dosage/*therapeutic use
MH  - Child
MH  - China
MH  - Combined Modality Therapy
MH  - Cytarabine/administration & dosage
MH  - Disease-Free Survival
MH  - Drug Evaluation
MH  - Drug Resistance, Neoplasm
MH  - Female
MH  - Granulocyte Colony-Stimulating Factor/administration & dosage
MH  - Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/drug therapy/surgery
MH  - Precursor Cell Lymphoblastic Leukemia-Lymphoma/*drug therapy/surgery
MH  - Recurrence
MH  - Retrospective Studies
MH  - *Salvage Therapy
MH  - Treatment Outcome
MH  - Young Adult
OTO - NOTNLM
OT  - CAG regimen
OT  - acute lymphocytic leukemia
OT  - relapse
OT  - salvage therapy
EDAT- 2013/04/26 06:00
MHDA- 2014/05/07 06:00
CRDT- 2013/04/26 06:00
PHST- 2012/12/24 00:00 [received]
PHST- 2013/03/10 00:00 [revised]
PHST- 2013/03/18 00:00 [accepted]
PHST- 2013/04/26 06:00 [entrez]
PHST- 2013/04/26 06:00 [pubmed]
PHST- 2014/05/07 06:00 [medline]
AID - 10.1002/hon.2051 [doi]
PST - ppublish
SO  - Hematol Oncol. 2013 Dec;31(4):206-12. doi: 10.1002/hon.2051. Epub 2013 Apr 25.